The Effects of Transfusion of Red blood cells In Sepsis

The Effects of Transfusion of Red blood cells In Sepsis - TETRIS, Transfusion in Sepsis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36804

Enrollment

100

Registered

2011-07-21

Start date

2011-11-23

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis + blood poisoning

Interventions

The transfusion of erythrocytes of

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who will receive their first erythrocyte transfusion on the ICU to correct for anemia

Exclusion criteria

Exclusion criteria: - Patients who have not given informed consent - Patients who pose difficulties in securing blood products (e.g. rare blood groups) - Patients who are actively bleeding or are suspected for active bleeding (when a transfusion is given with the intention to treat bleeding according to the treating physician) - Patients who receive more than 1 unit of red blood cells in the transfusion episode - Patients who need a blood transfusion when there*s no fresh blood available

Design outcomes

Primary

Measure	Time frame
Change in the expression of PS on erythrocytes before and after transfusion of erythrocytes	—

Secondary

Measure	Time frame
- Expression of erythrocyte CD44, CD47, CD55, CD59, Band 3, MFG-E8, Gas6, IgG, levels of heme and complement in blood - Expression of platelet CD62P, CD62E, CD63, and levels of microparticles sCD40L, sP-selectin, and thrombocyte-leukocyte complexes in blood and NBALF - Levels of hemoglobin, erythrocytes, platelets, leucocytes and leucodifferentiation in blood - Levels of fibrinogen, APTT, PTT and D-dimers in blood (to calculate DIC score) - Levels of ADAMTS13, active VWF and VWF multimer size in blood (experimental markers of DIC) - Levels of TAT-complexes, pro-thrombin fragment F1+2,factor VIIa, tissue factor in blood (markers of coagulation) - Levels of tissue type plasminogen activator inhibitor-1 (PAI-1) and plasmin-a2-antiplasmin complexes (PAP-complex) in blood (markers of fibrinolysis) - Sublingual microcirculatory density and perfusion velocity, as visualized with SDF - Tissue oxygenation, as measured with NIRS - Onset of TRALI - Time on mechanical ventilation - Duration of ICU stay - Duration of hospital stay - 28 day mortality	—

Measure

Time frame

- Expression of erythrocyte CD44, CD47, CD55, CD59, Band 3, MFG-E8, Gas6, IgG, levels of heme and complement in blood - Expression of platelet CD62P, CD62E, CD63, and levels of microparticles sCD40L, sP-selectin, and thrombocyte-leukocyte complexes in blood and NBALF - Levels of hemoglobin, erythrocytes, platelets, leucocytes and leucodifferentiation in blood - Levels of fibrinogen, APTT, PTT and D-dimers in blood (to calculate DIC score) - Levels of ADAMTS13, active VWF and VWF multimer size in blood (experimental markers of DIC) - Levels of TAT-complexes, pro-thrombin fragment F1+2,factor VIIa, tissue factor in blood (markers of coagulation) - Levels of tissue type plasminogen activator inhibitor-1 (PAI-1) and plasmin-a2-antiplasmin complexes (PAP-complex) in blood (markers of fibrinolysis) - Sublingual microcirculatory density and perfusion velocity, as visualized with SDF - Tissue oxygenation, as measured with NIRS - Onset of TRALI - Time on mechanical ventilation - Duration of ICU stay - Duration of hospital stay - 28 day mortality

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)